GRCE
Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.10
−1.87%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -44.5%
- EBIT
- -44.5%
- EPS
- -30.1%
- Free cash flow
- +21.4%
- Operating cash flow
- +21.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +64.4%
- EPS
- +57.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +53.4%
- EBIT
- +53.4%
- Net income
- +42.8%
- EPS
- +58.4%
- Free cash flow
- +40.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026